Literature DB >> 7756473

Dermatoses associated with travel to tropical countries: a prospective study of the diagnosis and management of 269 patients presenting to a tropical disease unit.

E Caumes1, J Carrière, G Guermonprez, F Bricaire, M Danis, M Gentilini.   

Abstract

The full spectrum of skin diseases related to travel in tropical areas is unknown. We prospectively studied 269 consecutive patients with travel-associated dermatosis who presented to our tropical disease unit in Paris during a 2-year period. The median age of these patients was 30 years; 137 patients were male; 76% of the patients were tourists; 38% had visited sub-Saharan Africa; and 85% had been appropriately vaccinated against tetanus. Cutaneous lesions appeared while the patient was still abroad in 61% of cases and after the patient's return to France in 39%. The diagnosis was definite in 260 cases; 137 of these cases (53%) involved an imported tropical disease. The most common diagnoses were cutaneous larva migrans (25%); pyodermas (18%); pruritic arthropod-reactive dermatitis (10%); myiasis (9%); tungiasis (6%); urticaria (5%); fever and rash (4%); and cutaneous leishmaniasis (3%). Hospitalization was necessary in 27 cases (10%), with a median duration of 5 days (range, 2-21 days). Travelers should be advised on how to avoid exposure to the agents and vectors of infectious dermatoses. Travel first-aid kits should include insect repellents and antibiotics effective against bacterial skin infections.

Entities:  

Mesh:

Year:  1995        PMID: 7756473     DOI: 10.1093/clinids/20.3.542

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  35 in total

1.  Cutaneous manifestations of infectious diseases: approach to the patient with fever and rash.

Authors:  C V Sanders; F A Lopez
Journal:  Trans Am Clin Climatol Assoc       Date:  2001

2.  Dermatologic Infectious Diseases in International Travelers.

Authors:  Mary E. Wilson; Lin H. Chen
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

Review 3.  [Therapy of tropical diseases after returning from travel].

Authors:  G D Burchard; H Sudeck
Journal:  Internist (Berl)       Date:  2003-05       Impact factor: 0.743

Review 4.  [Fever after travel return].

Authors:  I Schedel
Journal:  Internist (Berl)       Date:  2004-06       Impact factor: 0.743

5.  Excision of furuncular myiasis larvae using a punch: a simple, practical and aesthetic method.

Authors:  Gianne Pascoal; Fernanda Queiroz de Oliveira; Rosana Rocon Siqueira; Maria Gabriela Araújo Lopes; Marcelino Pereira Martins; Aloísio Carlos Couri Gamonal
Journal:  An Bras Dermatol       Date:  2016 May-Jun       Impact factor: 1.896

6.  Molecular characterization of Ancylostoma braziliense larvae in a patient with hookworm-related cutaneous larva migrans.

Authors:  Alexandre Le Joncour; Sandrine A Lacour; Gabriel Lecso; Stéphanie Regnier; Jacques Guillot; Eric Caumes
Journal:  Am J Trop Med Hyg       Date:  2012-05       Impact factor: 2.345

7.  Successful treatment of Old World cutaneous leishmaniasis caused by Leishmania infantum with posaconazole.

Authors:  A E Paniz Mondolfi; C Stavropoulos; T Gelanew; E Loucas; A M Perez Alvarez; G Benaim; B Polsky; G Schoenian; E M Sordillo
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

Review 8.  Mini review: Hookworm-related cutaneous larva migrans.

Authors:  H Feldmeier; A Schuster
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-09-16       Impact factor: 3.267

9.  Dermatoses among returned Canadian travellers and immigrants: surveillance report based on CanTravNet data, 2009-2012.

Authors:  Michael S Stevens; Jennifer Geduld; Michael Libman; Brian J Ward; Anne E McCarthy; Jean Vincelette; Wayne Ghesquiere; Jan Hajek; Susan Kuhn; David O Freedman; Kevin C Kain; Andrea K Boggild
Journal:  CMAJ Open       Date:  2015-01-13

10.  [Cutaneous larva migrans].

Authors:  N-P Hoff; R Mota; A Groffik; U R Hengge
Journal:  Hautarzt       Date:  2008-08       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.